ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma

The clinical efficiency of everolimus, an mammalian target of rapamycin (mTOR) inhibitor, is palliative as sequential or second-line therapy for renal cell carcinoma (RCC). However, the limited response of everolimus in RCC remains uncertain. In the present study, everolimus-resistant RCC models wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yun, Li, Wenzhi, Zhou, Juan, Zhang, Jin, Huang, Yiran, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374702/
https://www.ncbi.nlm.nih.gov/pubmed/30771617
http://dx.doi.org/10.1016/j.omtn.2019.01.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374702/
https://www.ncbi.nlm.nih.gov/pubmed/30771617
http://dx.doi.org/10.1016/j.omtn.2019.01.001

Ejemplares similares